Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Indian J Pharm Sci ; 75(2): 143-8, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24019561

RESUMO

The aim of this work was to develop the best formulations for naproxen suppositories. The effects of different bases and surfactants on the physicochemical characteristics of the suppositories were determined by several tests such as weight variation, melting point, assay, hardness, and release rate. All formulations met the standard criteria for tested physicochemical parameters; weight variation (97-112%), content uniformity (97-105%), melting point (4.66-8.7 min) and hardness tests (>5400 g). Based on release rate studies, hydrophilic, and lipophilic bases without surfactants were not suitable bases for naproxen suppository. Amongst the formulations containing surfactants only Witepsol H15 with 0.5% w/w of Tween 80 and Witepsol W35 with 0.5% of cetylpyridinium chloride were suitable and released nearly complete drug during 30 and 60 min, respectively. This study demonstrates the effects of incorporation of known agents on the in vitro release characteristics of naproxen suppository.

2.
Biomed Res Int ; 2013: 136859, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23984315

RESUMO

The main purpose of the present work was studying the biodistribution of amikacin solid lipid nanoparticles (SLNs) after pulmonary delivery to increase its concentration in the lungs for treatment of cystic fibrosis lung infections and also providing a new method for clinical application of amikacin. To achieve this aim, (99m)Tc labelled amikacin was loaded in cholesterol SLNs and after in vitro optimization, the desired SLNs and free drug were administered through pulmonary and i.v. routes to male rats and qualitative and biodistribution studies were done. Results showed that pulmonary delivery of SLNs of amikacin by microsprayer caused higher drug concentration in lungs than kidneys while i.v. administration of free drug caused reverse conditions. It seems that pulmonary delivery of SLNs may improve patients' compliance due to reduction of drug side effects in kidneys and elongation of drug dosing intervals due to the sustained drug release from SLNs.


Assuntos
Amicacina/administração & dosagem , Amicacina/farmacocinética , Lipídeos/farmacocinética , Pulmão/diagnóstico por imagem , Nanopartículas/química , Amicacina/sangue , Amicacina/farmacologia , Animais , Vias de Administração de Medicamentos , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Masculino , Nanopartículas/ultraestrutura , Tamanho da Partícula , Cintilografia , Ratos , Ratos Wistar , Tecnécio/administração & dosagem , Tecnécio/sangue , Tecnécio/farmacocinética , Tecnécio/farmacologia , Distribuição Tecidual/efeitos dos fármacos
3.
J Liposome Res ; 19(4): 310-21, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19863166

RESUMO

Cancer continues to be a major cause of morbidity and mortality worldwide. While discovery of new drugs and cancer chemotherapy opened a new era for the treatment of tumors, optimized concentration of drug at the target site is only possible at the expense of severe side effects. Nanoscale carrier systems have the potential to limit drug toxicity and achieve tumor localization. When linked with tumor-targeting moieties, such as tumor-specific ligands or monoclonal antibodies, the nanocarriers can be used to target cancer-specific receptors, tumor antigens, and tumor vasculatures with high affinity and precision. This article is an overview of advances and prospects in the applications of nanocarrier technology in cancer therapy. Applications of nanoliposomes, dendrimers, and nanoparticles in cancer therapy are explained, along with their preparation methods and targeting strategies.


Assuntos
Antineoplásicos/administração & dosagem , Portadores de Fármacos , Nanopartículas , Neoplasias/tratamento farmacológico , Antineoplásicos/uso terapêutico , Humanos
4.
Int J Pharm ; 308(1-2): 124-32, 2006 Feb 03.
Artigo em Inglês | MEDLINE | ID: mdl-16359833

RESUMO

Benzoyl peroxide (BPO) is commonly used in topical formulations for the treatment of acne and athletes foot. Skin irritation is a common side effect, and it has been shown that controlled release of BPO from a delivery system to the skin could reduce the side effect while reducing percutaneous absorption. Therefore, the aim of the present study was to produce ethylcellulose microparticles containing BPO which were able to control the release of BPO to the skin. In order to optimize the microparticle formulation, factors affecting the physical properties of microparticles were also investigated. Benzoyl peroxide microparticles were prepared using an emulsion solvent diffusion method by adding an organic internal phase containing benzoyl peroxide, ethyl cellulose and dichloromethane into a stirred aqueous phase containing polyvinyl alcohol. Drug content, particle size analysis and loading yield were determined in the prepared microparticles. BPO microparticles were then incorporated into standard vehicles for release studies. Scanning electron microscopy was used to study the shape and morphology of the microsponges. The micrograph of microsponges showed that they were spherical in shape and contained pores. These pores resulted from the diffusion of solvent from the surface of the microparticles and thus the particles were designated as microsponges. It was shown that the drug:polymer ratio, stirring rate, volume of dispersed phase influenced the particle size and drug release behavior of the formed microsponges and that the presence of emulsifier was essential for microsponge formation. The results showed that, generally, an increase in the ratio of drug:polymer resulted in a reduction in the release rate of BPO from microsponges which was attributed to a decreased internal porosity of the microsponges.


Assuntos
Peróxido de Benzoíla/química , Sistemas de Liberação de Medicamentos , Microesferas , Polímeros/química , Celulose/análogos & derivados , Celulose/química , Química Farmacêutica , Preparações de Ação Retardada , Emulsificantes/química , Cinética , Cloreto de Metileno/química , Pomadas , Porosidade , Solubilidade , Solventes/química , Propriedades de Superfície
5.
Int J Pharm ; 246(1-2): 171-7, 2002 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-12270619

RESUMO

Eudragit RS and RL are biocompatible non-swelling polymers that widely used in the preparation of sustained release drug delivery systems. In this study, the effect of thermal treating on the tensile strength of tablets and release of indomethacin from Eudragit RS and RL matrices were investigated. The results showed that thermal treating at 40 degrees C has no effect on the release of the drug, whereas heat-treating at temperatures higher than 50 or 60 degrees C decreases the release rate of indomethacin from Eudragit RS or RL, respectively. It was shown that the duration of the heat treatment was also an important factor in controlling the release rate of indomethacin from Eudragit matrices. The results showed that an increase in the duration of the heat treatment from 2 to 24 h resulted in a reduction in the release rate of the drug. The heating of the matrices over 24 h had no significant effect on the release rate of indomethacin. It was shown that heat treatment of the matrices over the glass transition temperature of the polymer can prolong the drug release but had no significant effect on the tensile strength of tablets.


Assuntos
Resinas Acrílicas/química , Calefação/métodos , Indometacina/química , Polímeros/química , Preparações de Ação Retardada , Portadores de Fármacos , Composição de Medicamentos , Microscopia Eletrônica de Varredura , Porosidade , Solubilidade , Comprimidos , Resistência à Tração , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...